Abstract
The current revival of the world’s economy is being predicated on social distancing, specifically the Six-Foot Rule, a guideline that offers little protection from pathogen-bearing aerosol droplets sufficiently small to be continuously mixed through an indoor space. The importance of airborne transmission of COVID-19 is now widely recognized. While tools for risk assessment have recently been developed, no safety guideline has been proposed to protect against it. We here build upon models of airborne disease transmission in order to derive an indoor safety guideline that would impose an upper bound on the “cumulative exposure time”, the product of the number of occupants and their time in an enclosed space. We demonstrate how this bound depends on the rates of ventilation and air filtration, dimensions of the room, breathing rate, respiratory activity and face-mask use of its occupants, and infectiousness of the respiratory aerosols. By synthesizing available data from the best characterized indoor spreading events with respiratory drop-size distributions, we estimate an infectious dose on the order of ten aerosol-borne virions. The new virus is thus inferred to be an order of magnitude more infectious than its forerunner (SARS-CoV), consistent with the pandemic status achieved by COVID-19. Case studies are presented for class-rooms and nursing homes, and a spreadsheet and online app are provided to facilitate use of our guideline. Implications for contact tracing and quarantining are considered, appropriate caveats enumerated. Particular consideration is given to respiratory jets, which may substantially elevate risk when face masks are not worn.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We confirm that all ethical guidelines have been followed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor revision to improve readability, including revised case-studies figure 3 and a glossary of mathematical symbols. Introduces a relative transmissibility to account for different age groups and the new viral strains.
Data Availability
An Excel spreadsheet is provided as a supplementary file to calculate our COVID-19 safety guideline for a specific indoor space. Expiratory aerosol droplet size distributions were taken from the cited literature, as either provided by the authors (Asadi et al, 2020) or digitally scanned from published figures (Morawska et al, 2009).
